Boston Scientific has completed its acquisition of a Swiss structural heart company and can immediately begin selling its systems.
The $435-million cash acquisition of Symetis SA, which focuses on minimally invasive transcatheter aortic valve implantation devices, was announced in March.
Symetis’ ACURATE valve products will join Boston Scientific’s interventional cardiology division, according to a Tuesday press release. The valves are designed to treat patients suffering from severe and symptomatic aortic valve stenosis, who are considered to be at high risk for surgical valve replacements. The valves are recognized as an alternative to open heart surgery.
Boston Scientific will continue to develop the ACURATE/neo/AS, which is currently in a clinical trial that will lead to a future approval in the European markets.
